查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827431

氣喘藥物市場（按產品類型、藥物類別、交付方式、分銷管道和最終用戶分類）—2025-2032 年全球預測

Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Distribution Channel, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年氣喘藥物市場將成長至 396.2 億美元，複合年成長率為 6.29%。

主要市場統計數據
基準年2024年 243億美元
預計2025年 257.5億美元
預測年份：2032年 396.2億美元
複合年成長率（%） 6.29%

對當前治療環境、設備創新、監管壓力和相關人員期望的權威定位，定義氣喘藥物策略

氣喘仍然是一種慢性呼吸系統疾病，其臨床和營運挑戰持續推動製藥和醫療設備領域的創新。雖然治療模式歷來著重於緩解症狀和預防病情惡化，但向精準醫療、改進的設備工程和整合護理模式的穩步轉變正在重塑臨床路徑和採購重點。在此背景下，從製造商到醫療保健提供者和付款人的相關人員正在重新評估產品系列、患者支援服務和分銷策略，以應對不斷變化的患者期​​望、監管要求和技術能力。

當代情勢反映了臨床科學與系統思維的交會。吸入器設計和連接技術的進步使得依從性監測和遠端系統管理成為可能，而不斷發展的臨床指導則鼓勵早期療育和分層治療選擇。同時，供應鏈考量、製造專業化和成本控制壓力促使人們重新評估採購和生產佈局。總而言之，這些動態變化為那些能夠在臨床可靠性、營運敏捷性和數據主導決策之間取得平衡的組織帶來了顛覆和機會。

設備與數位融合、個人化治療途徑、不斷變化的報銷優先順序以及供應鏈彈性如何重塑氣喘藥物的競爭優勢

氣喘藥物領域正在經歷一場變革，其驅動力在於多種力量的匯聚，這些力量正在重新定義競爭優勢和病患治療效果。首先，設備創新正在超越簡單的給藥機制，轉向整合的數位生態系統，將吸入器或霧化器與感測器、行動應用程式和雲端分析相結合。這一趨勢正在將價值提案從單純的產品交付轉向療效和參與度，透過加強藥物依從性追蹤，並在門診期間實現由醫療服務提供主導的干涉。

其次，隨著臨床醫生和付款方在中重度疾病的治療中優先考慮表現型和生物標記驅動的方法，臨床個人化治療正蓬勃發展。因此，治療途徑變得更加細緻，針對不同發炎特徵的患者，更傾向於採用標靶藥物和合併用藥策略。第三，監管和報銷格局正在演變，以獎勵現實世界的療效和成本控制，這增加了強力的上市後證據產生和付款方參與的重要性。此外，在全球經濟動盪之後，供應鏈的韌性和採購敏捷性變得越來越重要，迫使製造商重新評估其採購、庫存策略和本地製造方案。

最後，患者期望和醫療服務模式也在同步變化。遠端醫療的普及、護理分散化以及居家監測正在擴大氣喘管理的接觸點，因此需要能夠簡化使用並提高依從性的整合解決方案。總的來說，這些轉型有利於那些能夠將設備創新、臨床證據、供應鏈適應性以及與相關人員一致的價值命題整合到連貫的商業策略中的組織。

分析回顧 2025 年美國關稅如何影響氣喘藥物的採購成本、製造足跡和籌資策略

美國決定於2025年徵收新關稅，對氣喘藥物供應鏈、商業策略和長期投資選擇產生了多方面的影響。對某些原料、成品和零件徵收的進口關稅增加了某些依賴全球採購的製造商的到岸成本。因此，採購團隊和合約製造商加快了重新評估供應商協議、尋找近岸和國內替代方案以及協商長期供應協議的步伐，以降低成本波動。

因此，擁有垂直整合製造和多元化供應商基礎的製造商的穩定性有所提升，而那些集中於受影響進口類別的製造商則面臨營運壓力。為此，一些公司調整了資本投資的優先級，轉向本地設備生產線和組裝業務，同時在監管和品質合規成本與經濟效益之間取得平衡。此外，關稅主導的成本壓力影響了與經銷商和付款人的定價談判，導致相關人員強調附加價值服務，例如依從性計劃和病患支持，以保持其商業性地位。

從策略角度來看，關稅環境提升了採購和產品設計敏捷性的重要性。那些主動重新設計零件以使用替代材料和模組化架構的公司，其韌性更強。此外，重新分類零件、利用自由貿易協定以及增加庫存緩衝等過渡措施，也幫助一些公司吸收了短期衝擊。展望未來，這些政策變化的累積影響正促使人們重新思考供應鏈佈局策略、製造投資，以及在成本最佳化與依賴吸入器、霧化器和口服療法的患者持續護理之間的平衡。

綜合細分分析揭示了產品類型、藥品類別、交付方式、分銷管道和最終用戶人口統計數據如何影響臨床採用和商業策略

透過分析產品類型、藥品類別、給藥方式、分銷管道和最終用戶，可以揭示商業性和臨床動態。依產品類型分類，吸入器、霧化器和片劑到片劑製劑各自展現出不同的採用促進因素。吸入器和霧化器優先考慮設備人體工學、劑量準確性和促進依從性，而口服製劑則強調系統性耐受性和針對特定患者群體的便利性。因此，產品開發團隊必須將研發投資與設備可用性和病患偏好資料結合，以最大限度地提高臨床應用率。

依藥物類別檢視市場格局，突顯出獨特的治療和監管考量。沙丁胺醇和BETA受體促效劑主要用於急性症狀緩解和即時擴張支氣管，而支氣管擴張劑和皮質類固醇則構成需要長期依從性和安全性監測的維持治療方案的支柱。白三烯調節劑為某些發炎表現型提供了替代或輔助治療途徑，並可作為偏好或需要非吸入療法患者的口服選擇。因此，處方定位和臨床訊息必須區分急性救援治療和維持治療，同時考慮安全性和給藥途徑特異性的益處。

給藥方式大致分為吸入和口服，會影響臨床療效和病人接受度。吸入療法可將藥物靶向輸送至肺部，並可快速啟動給藥，但對患者的操作技能要求更高，並且可能需要高級培訓和後續隨訪。口服療法方便且易於患者熟悉，但可能存在不同的全身暴露和依從性挑戰。因此，商業化策略應加強對口服療法依從性的支持，同時整合病患教育舉措和吸入產品設備培訓計畫。

醫院藥局、線上藥局和零售藥局各自應對不同的採購行為和物流限制。醫院藥局通常在機構採購框架內處理急重症病例；線上藥局提供便利的訂閱模式，支持慢性病護理的連續性；而零售藥局在即時諮詢和即時取得方面仍然發揮著重要作用。因此，根據預測的處方模式和支付管道調整分銷策略，對於確保產品供應和患者依從性至關重要。

最後，將終端使用者細分為門診手術中心、家庭護理機構以及醫院和診所，凸顯了其多樣化的使用和支援需求。門診手術中心優先使用短效藥物進行術前和術後管理；居家照護機構需要耐用、易用且具有遠端監控功能的設備；醫院和診所則需要可靠的供應和全面的臨床支援材料。整合這些細分層級，有助於制定細緻的商業性策略，在產品設計、證據生成和服務交付之間取得平衡，以滿足臨床醫生、看護者和患者的期望。

美洲、中東和非洲以及亞太地區對監管複雜性、付款人期望和商業性執行的不同區域觀點

美洲、歐洲、中東和非洲以及亞太地區的動態正在影響監管途徑、報銷框架和商業性重點，為氣喘藥物相關人員創造了獨特的機會和限制。在美洲，付款方審查和採購的加強促使人們關注現實世界的療效、成本效益證據以及能夠顯著減少病情加重和住院的服務模式。在該地區營運的製造商優先考慮全面的衛生經濟學文獻和綜合的患者支持，以滿足處方決策者和大型綜合交付網路的需求。

歐洲、中東和非洲地區管理體制和報銷環境的差異性要求打入市場策略具有適應性。在一些歐洲國家，集中採購和基於價值的合約模式日益重要；而在中東和非洲部分地區，市場准入的挑戰和基礎設施的多樣性有利於建立穩固的經銷夥伴和開展能力建設項目。因此，跨境策略必須在集中式證據產生與本地客製化的付款人參與和供應鏈解決方案之間取得平衡。

亞太地區既具有快速應用的潛力，也面臨醫療保健體系、監管標準和病患群體多樣性的複雜性。該地區許多司法管轄區正在迅速採用數位醫療技術，為連網吸入器解決方案和遠端監控整合提供了肥沃的土壤。同時，製造商必須兼顧價格敏感度和當地製造業的預期，通常需要創造性的商業化模式、技術轉移和策略夥伴關係關係，以支持永續的可及性和規模化。在所有地區，協作證據產生、監管前瞻性和分銷規劃對於成功的市場滲透和長期的產品永續性仍然至關重要。

製藥公司、設備創新者參與企業如何透過產品服務捆綁、策略聯盟和證據主導的差異化競爭

氣喘藥物領域的競爭態勢體現了現有製藥公司、專業設備創新者、受託製造製造商以及新興數位醫療參與企業的混合競爭。關鍵的商業策略強調透過產品服務組合實現差異化，將可靠的藥理學與設備的易用性、依從性支持和真實世界證據生成相結合。投資長期病人參與解決方案和醫護人員教育的公司正在為替代藥物設置清晰的障礙，尤其是在維持治療領域，因為依從性和技術決定了臨床結果。

戰略夥伴關係和聯盟已成為加速連網型設備、雲端分析和專業製造等領域能力建構的常用機制。授權協議和聯合開發安排使成熟的藥物開發商能夠結合硬體和軟體專業知識，同時又不影響產品上市速度。同時，契約製造製造商和區域生產基地透過提供靈活的生產能力和合規的組裝服務，加快產品上市時間並提升供應鏈的穩健性，其戰略重要性日益凸顯。

產品平臺多元化也是一個顯著趨勢，各公司都在尋求改進醫療設備、聯合治療和強化患者支持計劃，以此作為傳統研發的補充。同時，競爭差異化越來越依賴透過上市後監測證​​明依從性、降低病情惡化率和成本效益高的治療途徑方面取得的可衡量的改善。能夠向付款人和醫療系統提供一致的臨床和經濟性陳述的公司，將最有可能確保藥物在處方集中的投放和長期使用。

為商業、製造和臨床領導者提供可行的策略步驟，以增強韌性、改善患者治療效果並推動與付款人一致的價值提案

產業領導者應優先考慮一系列切實可行的行動，將臨床價值與營運韌性和商業性敏捷性結合。首先，考慮將關鍵設備零件的製造業務外包，以多元化供應商基礎，並降低關稅相關成本上漲和全球物流中斷帶來的風險。此步驟應輔以情境規劃和靈活的合約模式，以便在必要時快速替換供應商。

第二，投資連網型設備功能和病人參與平台，實際提高依從性並獲得真實世界療效。此類投資將加強付款方對話，並為基於療效的合約創造機會。第三，將證據產生項目擴展到傳統的隨機試驗之外，納入真實世界臨床試驗、註冊庫以及反映付款者和提供者標準的健康經濟學分析。這些數據資產在與大型綜合交付網路和國家衛生系統進行合作談判時至關重要。

第四，調整你的市場進入策略，以反映你的通路的實際狀況和最終用戶的需求。相應地，為醫院藥劑師、零售團隊和居家照護提供者量身定做支援材料和培訓計劃。第五，選擇性地建立策略夥伴關係關係，以加速你的數位化和製造能力，而不是試圖在內部建立所有能力。最後，儘早與監管機構和付款人溝通，使你的臨床開發計畫與報銷要求保持一致，從而降低產品上市後長期面臨市場接受障礙的風險。這些綜合行動可以為將競爭考察轉化為永續競爭優勢提供切實可行的藍圖。

結合相關人員訪談、監管機構調查、證據綜合和情境分析的嚴格混合方法研究途徑確保了可靠且可操作的見解

本報告所依據的研究結合了多種定性和定量方法，以確保可靠的三段論見解。主要研究包括與各類相關人員進行結構化訪談：執業肺科醫生、呼吸治療師、醫院採購負責人、藥屋主任、付款人以及製造商和設備公司的高級商務領導。此外，我們還與臨床醫生和付款人舉行了諮詢圓桌會議，以檢驗實踐模式和報銷優先順序的解釋。

二次研究包括對官方監管指南、臨床實踐指南、產品標籤和同行評審文獻的系統性回顧，以建立全面的依證。產業期刊、監管備案文件和企業資料有助於了解競爭格局和產品線動態。數據合成遵循三角測量框架，將主要見解與文獻證據交叉引用，以識別趨同主題並減少偏差。

分析方法包括對訪談記錄進行定性主題編碼、情境分析（用於檢驗備選假設下供應鏈和資費的影響）以及付款人路徑圖譜繪製（用於捕捉區域報銷的細微差別）。在適用的情況下，我們也進行了敏感度分析，以評估設備採用和證據產生對處方藥目錄投放的行為影響。我們也進行了品質保證，以確保調查結果的一致性和可追溯性，包括對調查方法和調查記錄進行獨立審查。

結論性綜合表明，設備創新、現實世界證據和有彈性的供應鏈對於氣喘藥物的永續成功至關重要

總而言之，氣喘藥物領域正處於曲折點，設備發展、新興證據、監管環境的細微變化以及供應鏈策略將共同決定商業性可行性和患者影響。透過採用連網型設備技術、投資上市後證據並強化供應鏈，整合這些因素的機構將能夠更好地滿足臨床醫生和付款人的期望，同時提高患者的依從性和療效。

此外，政策和經濟環境，包括關稅主導的成本壓力和區域准入動態，凸顯了敏捷性和前瞻性營運選擇的重要性。透過調整產品設計以適應分銷現實和臨床實踐模式，公司可以製定引人注目的價值提案，引起醫院、居家醫療機構和藥房等相關人員的共鳴。積極主動地建立策略夥伴關係關係，滿足付款人證據要求，並嚴格執行，可以將洞察轉化為對患者和醫療保健系統永續的價值。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大雙支氣管擴張劑吸入器在中度至重度氣喘治療的應用
  • 數位吸入器感測器的成長實現了即時藥物依從性追蹤和數據分析
  • 針對新型白細胞介素路徑治療氣喘的生物單株抗體研發管線不斷擴大
  • 越來越多的患者喜歡每日一次的固定劑量複合式吸入器，而不是多劑量方案
  • COVID-19 疫情對遠端醫療氣喘護理和遠端患者監護的影響
  • 非專利吸入皮質類固醇的監管核准正在推動現有市場的價格競爭

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章氣喘藥物市場（依產品類型）

  • 吸入器
  • 噴霧器
  • 藥片和藥丸

第9章氣喘藥物市場（依藥物類別）

  • 沙丁胺醇
  • BETA-促效劑
  • 支氣管擴張劑
  • 皮質類固醇
  • 白三烯調節劑

第10章氣喘藥物市場按交付方式

  • 吸入
  • 口服

第 11 章氣喘藥物市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 12 章氣喘藥物市場（依最終使用者）

  • 門診手術中心
  • 居家照護環境
  • 醫院和診所

第13章氣喘藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章氣喘藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各國氣喘藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • ALK-Abello A/S
    • Amphastar Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • CHIESI Farmaceutici SpA
    • Cipla Limited
    • Dr.Reddy's Laboratories Ltd
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Hetero Labs Limited
    • Lallemand Inc.
    • Merck KGaA
    • Mundipharma International Limited
    • NIOX Group PLC
    • Novartis AG
    • Novo Holdings
    • OPKO Health, Inc.
    • Pfizer Inc.
    • Sanner GmbH
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Verona Pharma PLC
    • Viatris, Inc.
Product Code: MRR-434CCDA05226

The Asthma Drugs Market is projected to grow by USD 39.62 billion at a CAGR of 6.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.30 billion
Estimated Year [2025] USD 25.75 billion
Forecast Year [2032] USD 39.62 billion
CAGR (%) 6.29%

An authoritative orientation to the current therapeutic environment, device innovation, regulatory pressures, and stakeholder expectations that define asthma drug strategies

Asthma remains a chronic respiratory condition with persistent clinical and operational challenges that continue to drive innovation across pharmaceutical and device sectors. Treatment paradigms have historically centered on symptom relief and exacerbation prevention, but a steady shift toward precision therapeutics, improved device engineering, and integrated care models is reshaping clinical pathways and procurement priorities. Against this backdrop, stakeholders from manufacturers to providers and payers are reassessing product portfolios, patient support services, and distribution strategies to respond to changing patient expectations, regulatory requirements, and technological possibilities.

The contemporary landscape reflects an intersection of clinical science and systems thinking. Advances in inhaler design and connectivity are enabling adherence monitoring and remote management, while evolving clinical guidance encourages earlier intervention and stratified therapy selection. Concurrently, supply chain considerations, manufacturing specialization, and cost containment pressures are prompting reassessments of sourcing and production footprints. Taken together, these dynamics have created both disruption and opportunity for organizations that can combine clinical credibility with operational agility and data-driven decision making.

How device-digital convergence, personalized treatment pathways, evolving reimbursement priorities, and supply chain resilience are reshaping competitive advantage in asthma therapeutics

The asthma therapeutics environment is experiencing transformative inflection driven by several converging forces that are redefining competitive advantage and patient outcomes. First, device innovation has moved beyond simple delivery mechanics toward integrated digital ecosystems that pair inhalers and nebulizers with sensors, mobile applications, and cloud analytics. This trend enhances medication adherence tracking and enables provider-led interventions between visits, thereby shifting value propositions toward outcomes and engagement rather than product-only offerings.

Second, clinical personalization is gaining momentum as clinicians and payers prioritize phenotype- and biomarker-driven approaches for moderate to severe disease management. Consequently, treatment pathways are becoming more nuanced, favoring targeted agents and combination strategies for patients with distinct inflammatory profiles. Third, regulatory and reimbursement landscapes are evolving to reward real-world effectiveness and cost containment, which increases the importance of robust post-market evidence generation and payer engagement. Moreover, supply chain resilience and procurement agility have grown in importance following global disruptions, prompting manufacturers to reassess sourcing, inventory strategies, and local manufacturing options.

Finally, patient expectations and care delivery models are shifting in parallel. Telehealth adoption, decentralized care, and home-based monitoring have expanded the touchpoints for asthma management and require integrated solutions that simplify use and improve adherence. In sum, these transformative shifts favor organizations that can integrate device innovation, clinical evidence, supply chain adaptability, and stakeholder-aligned value propositions into coherent commercial strategies.

An analytical review of how the United States tariff measures enacted in 2025 have influenced sourcing costs, manufacturing footprints, and procurement strategies across asthma therapeutics

The policy decision to implement new tariffs in the United States in 2025 has had multifaceted implications for the asthma therapeutics supply chain, commercial strategies, and long-term investment choices. Import duties on select raw materials, finished devices, and components increased landed costs for certain manufacturers that rely on globalized sourcing. As a result, procurement teams and contract manufacturers accelerated efforts to re-evaluate supplier contracts, identify nearshore and domestic alternatives, and negotiate longer-term supply agreements to mitigate cost volatility.

Consequently, manufacturers with vertically integrated manufacturing or diversified supplier bases found greater stability, while those with concentrated exposure to affected import categories faced operational pressure. In response, several organizations prioritized reprioritization of capital spend toward local production lines for devices and assembly operations, even as they continued to balance unit economics against regulatory and quality compliance costs. Moreover, tariff-driven cost pressures have influenced pricing discussions with distributors and payers, encouraging stakeholders to emphasize value-added services such as adherence programs and patient support to sustain commercial positioning.

From a strategic standpoint, the tariff environment amplified the importance of agility in sourcing and product design. Firms that proactively redesigned components to use alternative materials or modular architectures saw improved resilience. Additionally, transitional measures-such as re-classifying components, leveraging free trade agreements where applicable, and increasing inventory buffers-helped some organizations absorb short-term shocks. Looking forward, the cumulative impact of these policy changes is prompting long-term reconsideration of supply chain footprint strategies, manufacturing investments, and the balance between cost optimization and continuity of care for patients reliant on inhalers, nebulizers, and oral therapies.

Integrated segmentation analysis revealing how product types, drug classes, delivery modes, distribution channels, and end-user contexts shape clinical adoption and commercial strategies

Segmentation insights reveal distinct commercial and clinical dynamics when examined through product type, drug class, delivery mode, distribution channel, and end-user lenses. When framed by product type, inhalers, nebulizers, and tablets and pills demonstrate divergent adoption drivers: inhalers and nebulizers prioritize device ergonomics, dosing accuracy, and adherence facilitation, while oral formulations emphasize systemic tolerability and convenience for particular patient cohorts. As a result, product development teams must align R&D investments with device usability and patient preference data to maximize clinical uptake.

Viewing the landscape by drug class highlights unique therapeutic and regulatory considerations. Albuterol and beta agonists primarily address acute symptom relief and immediate bronchodilation needs, whereas bronchodilators and corticosteroids form the backbone of maintenance regimens that require longitudinal adherence and safety monitoring. Leukotriene modifiers offer alternative or adjunctive pathways for specific inflammatory phenotypes and can be positioned as oral options for patients who prefer or require noninhaled therapy. Therefore, formulary positioning and clinical messaging must differentiate acute rescue therapies from maintenance approaches while accounting for safety profiles and route-specific advantages.

Delivery mode-classified broadly as inhalable or oral-shapes both clinical outcomes and patient acceptance. Inhalable therapies offer targeted pulmonary deposition and rapid onset, but they demand patient technique competency and sometimes a higher degree of training and follow-up. Oral therapies provide convenience and familiar dosing formats but may present different systemic exposure profiles and adherence challenges. Consequently, commercialization strategies should integrate patient education initiatives and device training programs for inhalable products while reinforcing adherence supports for oral regimens.

Distribution channel considerations further inform go-to-market approaches, with hospital pharmacies, online pharmacies, and retail pharmacies each serving distinct buyer behaviors and logistical constraints. Hospital pharmacies often handle acute and high-acuity cases with institutional purchasing frameworks, online pharmacies provide convenience and subscription models that support chronic therapy continuity, and retail pharmacies remain critical for point-of-care counseling and immediate access. Aligning distribution strategies with anticipated prescribing patterns and payer pathways is therefore essential for maintaining product availability and patient adherence.

Finally, end-user segmentation across ambulatory surgery centers, home care settings, and hospitals and clinics underscores varied utilization contexts and support requirements. Ambulatory surgery centers may prioritize short-acting agents for peri-procedural management, home care settings demand durable and easy-to-use devices with remote monitoring capabilities, and hospitals and clinics require high-reliability supply and comprehensive clinical support materials. Integrating these segmentation layers supports a nuanced commercial playbook that balances product design, evidence generation, and service delivery to meet the expectations of clinicians, caregivers, and patients.

A regionally differentiated perspective on regulatory complexity, payer expectations, and commercial execution across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence regulatory pathways, reimbursement frameworks, and commercial priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, creating distinct opportunities and constraints for asthma therapeutics stakeholders. In the Americas, payer scrutiny and procurement sophistication drive an emphasis on real-world outcomes, cost-effectiveness evidence, and service models that demonstrably reduce exacerbations and hospital admissions. Manufacturers operating in this region are prioritizing comprehensive health economic dossiers and integrated patient support to satisfy formulary decision-makers and large integrated delivery networks.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments necessitate adaptive market entry strategies. In some European countries, centralized procurement and value-based contracting play increasing roles, while in parts of the Middle East and Africa, access challenges and infrastructure variability favor robust distribution partnerships and capacity-building programs. Consequently, cross-border strategies must balance centralized evidence generation with locally tailored payer engagement and supply chain solutions.

The Asia-Pacific region presents both rapid adoption potential and complexity due to diverse healthcare systems, regulatory standards, and patient demographics. Many jurisdictions in this region are fast adopters of digital health technologies, providing fertile ground for connected inhaler solutions and remote monitoring integration. At the same time, manufacturers must navigate price sensitivity and local manufacturing expectations, which often require creative commercialization models, technology transfers, and strategic partnerships to support sustainable access and scale. Across all regions, coordinated evidence generation, regulatory foresight, and distribution planning remain central to successful market penetration and long-term product sustainability.

How incumbent pharmaceutical firms, device innovators, and digital entrants are competing through product-service bundles, strategic alliances, and evidence-driven differentiation

Competitive dynamics in the asthma therapeutics arena reflect a blend of established pharmaceutical incumbents, specialized device innovators, contract manufacturing organizations, and emerging digital health entrants. Leading commercial strategies emphasize differentiation through product-service bundles that combine reliable pharmacology with device usability, adherence supports, and real-world evidence generation. Firms that invest in longitudinal patient engagement solutions and provider education create distinct barriers to substitution, particularly for maintenance therapies where adherence and technique determine clinical outcomes.

Strategic partnerships and alliances have become common mechanisms to accelerate capability building in areas such as connected devices, cloud analytics, and specialty manufacturing. Licensing agreements and co-development arrangements allow established drug developers to integrate hardware and software expertise without sacrificing speed to market. At the same time, contract manufacturers and regional production hubs have increased their strategic importance by offering flexible capacity and regulatory-compliant assembly services that reduce time-to-shelf and improve supply chain robustness.

Product pipeline diversification is also a notable trend, with organizations pursuing incremental device improvements, combination therapies, and enhanced patient support programs as complementary levers to traditional R&D. Meanwhile, competitive differentiation increasingly rests on the ability to demonstrate measurable improvements in adherence, reduction in exacerbations, and cost-effective care pathways through robust post-market studies. Firms that can present coherent clinical and economic narratives to payers and health systems will be best positioned to secure formulary placement and long-term utilization.

Actionable strategic steps for commercial, manufacturing, and clinical leaders to build resilience, enhance patient outcomes, and drive payer-aligned value propositions

Industry leaders should prioritize a set of pragmatic actions that align clinical value with operational resilience and commercial agility. First, diversify supplier bases and consider nearshoring manufacturing for critical device components to reduce exposure to tariff-related cost spikes and global logistics disruptions. This step should be complemented by scenario planning and flexible contracting models that allow rapid supplier substitution when necessary.

Second, invest in connected-device capabilities and patient engagement platforms that demonstrably improve adherence and collect real-world outcomes. Such investments can strengthen payer conversations and create opportunities for outcomes-based contracting. Third, expand evidence-generation programs beyond classical randomized trials to include real-world studies, registries, and health economics analyses that reflect payer and provider decision criteria. These data assets will be critical when negotiating placement with large integrated delivery networks and national health systems.

Fourth, calibrate go-to-market strategies to reflect distribution channel realities and end-user needs; tailor support materials and training programs for hospital pharmacists, retail teams, and home-care providers accordingly. Fifth, pursue selective strategic partnerships to accelerate digital and manufacturing capabilities rather than attempting to build all competencies internally. Finally, engage regulators and payers early to align clinical development plans with reimbursement requirements, reducing the risk of protracted uptake barriers following product launch. Together, these actions offer a pragmatic roadmap for converting insights into durable competitive advantage.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, evidence synthesis, and scenario analysis to ensure credible actionable insights

The research underpinning this report combined multiple qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research included structured interviews with a range of stakeholders: practicing pulmonologists, respiratory therapists, hospital procurement officers, pharmacy directors, payers, and senior commercial leaders from manufacturers and device firms. These interviews were complemented by advisory roundtables with clinicians and payers to validate interpretation of practice patterns and reimbursement priorities.

Secondary research encompassed systematic reviews of public regulatory guidance, clinical practice guidelines, product labeling, and peer-reviewed literature to construct a comprehensive evidence baseline. Trade publications, regulatory filings, and corporate disclosures aided understanding of competitive posture and pipeline dynamics. Data synthesis followed a triangulation framework in which primary insights were cross-referenced with documentary evidence to identify convergent themes and reduce bias.

Analytical methods included qualitative thematic coding for interview transcripts, scenario analysis to test supply chain and tariff impacts under alternative assumptions, and payer pathway mapping to capture regional reimbursement nuances. Where applicable, sensitivity analyses were performed to assess the behavioral implications of device adoption and evidence generation on formulary positioning. Throughout, quality assurance measures ensured consistency and traceability of findings, including independent review of methodology and source logs.

A conclusive synthesis underscoring why device innovation, real-world evidence, and resilient supply chains are essential to sustainable success in asthma therapeutics

In conclusion, the asthma therapeutics landscape is at an inflection point where device evolution, evidence generation, regulatory nuance, and supply chain strategy jointly determine commercial viability and patient impact. Organizations that integrate these dimensions-by deploying connected-device technologies, investing in post-market evidence, and fortifying supply chains-will be better equipped to meet clinician and payer expectations while improving adherence and outcomes for patients.

Moreover, the policy and economic environment, including tariff-driven cost pressures and regional access dynamics, underscores the need for agility and forward-looking operational choices. By aligning product design with distribution realities and clinical practice patterns, companies can create defensible value propositions that resonate with stakeholders across hospitals, home care settings, and pharmacies. The path forward favors firms that are proactive in forming strategic partnerships, responsive to payer evidence requirements, and disciplined in execution, thereby translating insight into sustainable value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding use of dual bronchodilator inhalers for moderate to severe asthma management
  • 5.2. Growth of digital inhaler sensors enabling real time adherence tracking and data analytics
  • 5.3. Rising pipeline of biologic monoclonal antibodies targeting novel interleukin pathways in asthma treatment
  • 5.4. Increasing patient preference for once daily fixed dose combination inhalers over multiple dosing regimens
  • 5.5. Impact of COVID 19 pandemic on telehealth driven asthma care and remote patient monitoring adoption
  • 5.6. Regulatory approvals of generic inhaled corticosteroids driving price competition in established markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Asthma Drugs Market, by Product Type

  • 8.1. Inhalers
  • 8.2. Nebulizers
  • 8.3. Tablets & Pills

9. Asthma Drugs Market, by Drug Class

  • 9.1. Albuterol
  • 9.2. Beta Agonists
  • 9.3. Brochodilators
  • 9.4. Corticosteroids
  • 9.5. Leukotriene Modifiers

10. Asthma Drugs Market, by Delivery Mode

  • 10.1. Inhalable
  • 10.2. Oral

11. Asthma Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Asthma Drugs Market, by End Users

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Home Care Settings
  • 12.3. Hospitals & Clinics

13. Asthma Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Asthma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. ALK-Abello A/S
    • 16.3.2. Amphastar Pharmaceuticals, Inc.
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Bayer AG
    • 16.3.5. Boehringer Ingelheim International GmbH
    • 16.3.6. CHIESI Farmaceutici S.p.A.
    • 16.3.7. Cipla Limited
    • 16.3.8. Dr.Reddy's Laboratories Ltd
    • 16.3.9. F. Hoffmann-La Roche Ltd.
    • 16.3.10. GlaxoSmithKline PLC
    • 16.3.11. Hetero Labs Limited
    • 16.3.12. Lallemand Inc.
    • 16.3.13. Merck KGaA
    • 16.3.14. Mundipharma International Limited
    • 16.3.15. NIOX Group PLC
    • 16.3.16. Novartis AG
    • 16.3.17. Novo Holdings
    • 16.3.18. OPKO Health, Inc.
    • 16.3.19. Pfizer Inc.
    • 16.3.20. Sanner GmbH
    • 16.3.21. Sanofi S.A.
    • 16.3.22. Sunovion Pharmaceuticals Inc.
    • 16.3.23. Teva Pharmaceutical Industries Ltd.
    • 16.3.24. Verona Pharma PLC
    • 16.3.25. Viatris, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ASTHMA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ASTHMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ASTHMA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 223. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 229. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 230. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 231. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 234. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 259. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 266. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 267. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 270. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 271. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 278. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 279. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 282. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 300. CANADA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 301. CANADA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. CANADA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. CANADA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 304. CANADA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. MEXICO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 311. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. MEXICO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 321. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. BRAZIL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 324. BRAZIL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 339. GERMANY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 340. GERMANY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 341. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 342. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 343. GERMANY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 344. GERMANY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 345. FRANCE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. FRANCE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. FRANCE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 348. FRANCE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 349. FRANCE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 350. FRANCE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 351. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. FRANCE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 354. FRANCE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 355. RUSSIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 356. RUSSIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 357. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 358. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 359. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 360. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 361. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 362. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 363. RUSSIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 364. RUSSIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (US